Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
First Year of Commercialization, Alphamab Oncology Reports Full Year 2021 Financial Results and Business Highlights 2022-03-30 10:35
Alphamab Oncology to Present Clinical Data of KN026 Combined with KN046 in HER2-positive Solid Tumors at AACR 2022 2022-03-09 09:14
Alphamab Oncology Announced Publication of Clinical Results of KN026 in HER2-positive Breast Cancer in Clinical Cancer Research 2022-02-24 09:41
Alphamab Oncology Announced IND Approval of PD-L1/OX40 Bispecific Antibody KN052 2022-02-11 09:31
Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046 2022-01-13 10:46
IND Approved for Pivotal Clinical Study of HER2 Bispecific Antibody KN026 Combined with Chemotherapy in Gastric Cancer 2022-01-05 11:49
Alphamab Oncology Announced First Patient Dosed in the U.S. in A Phase II Pivotal Clinical Study of KN046 2021-12-23 09:13
Posters Highlighting clinical data of KN026 presented at SABCS 2021 2021-12-09 12:20
IND Application for Phase 3 Registration Study of KN046 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer was Approved by CDE 2021-11-24 09:35
Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC 2021-10-29 09:36
IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE 2021-10-21 10:31
Alphamab Oncology Completed Enrollment in the First Pivotal Phase III Clinical Study of the Bispecific Antibody KN046 2021-10-18 10:19
Alphamab Oncology Reports 2021 Interim Results and Business Highlights 2021-08-30 10:51
Alphamab Oncology and CSPC Achieved an Licensing Cooperation on Anti-HER2 Bispecific Antibody KN026 in Mainland China 2021-08-24 15:08
Subcutaneously Injected PD-L1 Antibody Envafolimab (KN035) Obtained Its Second Orphan Drug Designation From The U.S. FDA 2021-06-30 08:55
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021 2021-06-07 10:11
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021 2021-06-07 10:10
Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021 2021-06-07 09:53
Poster to Highlight ENVASARC Pivotal Trial of Envafolimab (KN035) will be presented at the 2021 ASCO Annual Meeting 2021-05-24 08:54
Alphamab Oncology to Present Multiple Clinical Research Data at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021) 2021-05-20 09:34
1 2 3 4